MIAMI--(BUSINESS WIRE)--
OPKO Health, Inc. (NYSE: OPK), a multinational biopharmaceutical and
diagnostics company, will release operating and financial results for
the three months ended March 31, 2016, after the close of the U.S.
financial markets on Monday, May 9, 2016.
OPKO's senior management will provide a business update and discuss its
results in greater detail in a conference call and live audio webcast at
4:30 p.m. Eastern time on Monday, May 9, 2016.
The conference call dial-in information is listed below. To access the
webcast, please log on to the OPKO website at www.opko.com
at least 15 minutes prior to the start of the call to ensure adequate
time for any software downloads that may be required.
CONFERENCE CALL & WEBCAST INFORMATION
WHEN: Monday, May 9, 2016, 4:30 p.m. ET
DOMESTIC DIAL-IN: (866)
634-2258
INTERNATIONAL DIAL-IN: (330) 863-3454
PASSCODE:
2590322
For those unable to participate in the conference call or webcast, a
replay will be available beginning May 9, 2016 at 7:30 p.m. ET until May
15, 2016 at 11:59 p.m. ET. To access the replay, dial (855) 859-2056 or
(404) 537-3406. The replay passcode is: 2590322.
The replay can also be accessed for a period of time on OPKO's website
at www.opko.com.
About OPKO Health, Inc.
OPKO Health, Inc. is a diversified healthcare company that seeks to
establish industry-leading positions in large, rapidly growing markets.
Our diagnostics business includes Bio-Reference Laboratories, the
nation's third-largest clinical laboratory with a core genetic testing
business and a 420-person sales force to drive growth and leverage new
products, including the 4Kscore® prostate cancer test and the Claros®1
in-office immunoassay platform. Our pharmaceutical business features
Rayaldee®, a treatment for SHPT in stage 3-4 CKD patients
with vitamin D insufficiency (PDUFA date is October 22, 2016) and
VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation
launched by partner Tesaro, IV formulation in Phase 3). Our biologics
business includes hGH-CTP, a once-weekly human growth hormone injection
(in Phase 3 and partnered with Pfizer), a long-acting Factor VIIa drug
for hemophilia (in Phase 2a) and a long acting oxyntomodulin for
diabetes and obesity (in Phase 1). We also have production and
distribution assets worldwide, multiple strategic investments and an
active business development strategy. More information is available at www.opko.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160428006934/en/
